| Name | Pyronaridine tetraphosphate |
| Description | Pyronaridine tetraphosphate is an orally active, mannitol-containing inhibitor of DNA topoisomerase 2 and erythrocyte cytokine with antimalarial and antitumour activity.Pyronaridine tetraphosphate treats P. falciparum and Echinococcus granulosus infections. Pyronaridine tetraphosphate treats P. falciparum and Echinococcus granulosus infections and attenuates Ebola virus transmission. |
| In vitro | With an IC50 value of 1.53-3.94 nM, pyronaridine tetraphosphate (24 h) exhibits anti-P. falciparum activity[2]. |
| In vivo | Reducing the parasitic burden in Echinococcus granulosus-infected mice, pyronaridine tetraphosphate (57 mg/kg, oral administration, q.d. for 30 days) has been demonstrated[1].Reducing the parasitic burden in secondarily infected (cysts) mice, pyronaridine tetraphosphate (57 mg/kg, intraperitoneal injection, q.d. for 3 days) has shown efficacy[1].Exhibiting a higher exposure in the liver than in the plasma in male ICR mice, pyronaridine tetraphosphate (57 mg/kg, intraperitoneal injection, for a single dose) has been observed[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 20 mg/mL (21.98 mM), Sonication is recommended.
DMSO : 10 mg/mL (10.99 mM), Sonication is recommended.
|
| Keywords | Pyronaridine | Pyronaridine tetraphosphate |
| Inhibitors Related | Berberine chloride | EIDD-1931 | Flumequine | Norfloxacin | Prulifloxacin | Enoxacin | Pefloxacin Mesylate | Ciprofloxacin | Ciprofloxacin monohydrochloride | Etoposide |
| Related Compound Libraries | Anti-Parasitic Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
United States
